DekaBank Deutsche Girozentrale boosted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 41.4% during the second quarter, Holdings Channel reports. The institutional investor owned 505,635 shares of the medical equipment provider’s stock after buying an additional 148,105 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Hologic were worth $23,054,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of HOLX. Chevy Chase Trust Holdings Inc. increased its stake in shares of Hologic by 3.6% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 240,769 shares of the medical equipment provider’s stock valued at $10,245,000 after buying an additional 8,289 shares in the last quarter. Gulf International Bank UK Ltd increased its stake in shares of Hologic by 1.5% in the first quarter. Gulf International Bank UK Ltd now owns 74,164 shares of the medical equipment provider’s stock valued at $3,155,000 after buying an additional 1,100 shares in the last quarter. National Pension Service increased its stake in shares of Hologic by 55,168.1% in the first quarter. National Pension Service now owns 244,285 shares of the medical equipment provider’s stock valued at $10,433,000 after buying an additional 243,843 shares in the last quarter. Fox Run Management L.L.C. increased its stake in shares of Hologic by 117.2% in the first quarter. Fox Run Management L.L.C. now owns 12,600 shares of the medical equipment provider’s stock valued at $536,000 after buying an additional 6,800 shares in the last quarter. Finally, Graybill Bartz & Assoc Ltd. increased its stake in shares of Hologic by 1.5% in the first quarter. Graybill Bartz & Assoc Ltd. now owns 59,185 shares of the medical equipment provider’s stock valued at $2,518,000 after buying an additional 885 shares in the last quarter. Institutional investors own 94.46% of the company’s stock.

Hologic, Inc. (HOLX) opened at 38.20 on Friday. The firm has a market cap of $10.71 billion, a P/E ratio of 14.23 and a beta of 0.90. The firm’s 50-day moving average price is $43.73 and its 200-day moving average price is $42.89. Hologic, Inc. has a 1-year low of $35.15 and a 1-year high of $46.80.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.49 by $0.01. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The business had revenue of $806.10 million during the quarter, compared to the consensus estimate of $799.70 million. During the same quarter last year, the firm earned $0.51 earnings per share. The business’s revenue for the quarter was up 12.4% on a year-over-year basis. Equities research analysts anticipate that Hologic, Inc. will post $2.01 earnings per share for the current fiscal year.

WARNING: “DekaBank Deutsche Girozentrale Increases Position in Hologic, Inc. (NASDAQ:HOLX)” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/dekabank-deutsche-girozentrale-increases-position-in-hologic-inc-nasdaqholx/1478123.html.

HOLX has been the subject of several research reports. Canaccord Genuity restated a “buy” rating and issued a $53.00 target price on shares of Hologic in a research note on Tuesday, May 9th. Stifel Nicolaus raised their target price on Hologic from $45.00 to $48.00 and gave the company a “buy” rating in a research note on Thursday, May 11th. BTIG Research restated a “buy” rating and issued a $47.00 target price on shares of Hologic in a research note on Sunday, May 14th. Zacks Investment Research downgraded Hologic from a “buy” rating to a “hold” rating in a research note on Tuesday, May 23rd. Finally, Jefferies Group LLC set a $49.00 target price on Hologic and gave the company a “buy” rating in a research note on Sunday, May 28th. One analyst has rated the stock with a sell rating, five have issued a hold rating and nine have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $48.64.

In other Hologic news, insider Peter J. Valenti III sold 10,005 shares of the firm’s stock in a transaction that occurred on Tuesday, May 30th. The shares were sold at an average price of $43.44, for a total transaction of $434,617.20. Following the completion of the transaction, the insider now owns 20,994 shares of the company’s stock, valued at $911,979.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Elaine Ullian sold 6,902 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $40.12, for a total transaction of $276,908.24. Following the transaction, the director now directly owns 23,810 shares of the company’s stock, valued at approximately $955,257.20. The disclosure for this sale can be found here. Insiders have sold 60,627 shares of company stock valued at $2,632,911 in the last ninety days. Insiders own 0.79% of the company’s stock.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.